NRG Oncology/RTOG1205:贝伐珠单抗联合同步再程放疗对比贝伐珠单抗单药治疗复发性胶质母细胞瘤的随机II期试验
NRG Oncology/RTOG1205是一项前瞻性随机II期试验,纳入182例复发性胶质母细胞瘤患者(170例符合分析),随机接受再程放疗(35 Gy/10次)联合同步贝伐珠单抗(10 mg/kg 每2周)或贝伐珠单抗单药治疗。结果显示联合组6个月无进展生存率从29.1%提高至54.3%(P=.001),但总生存无改善(HR 0.98,P=.46)。治疗耐受良好,急性3级及以上治疗相关不良事件发生率为5%,无迟发性高级别不良事件。
要点
- 再程放疗联合同步贝伐珠单抗较贝伐珠单抗单药改善6个月无进展生存率(54.3% vs 29.1%,P=.001)。
- 总生存无显著改善:中位总生存10.1个月 vs 9.7个月(HR 0.98,80%CI 0.79–1.23,P=.46)。
- 治疗耐受良好:急性3级及以上治疗相关不良事件发生率5%,无迟发性高级别不良事件。
核心结论
- 再程放疗安全且耐受良好,贝伐珠单抗联合再程放疗在无进展生存方面有临床意义的改善,特别是6个月无进展生存率,但总生存无差异。
研究设计与样本
- NRG Oncology/RTOG1205是一项前瞻性、II期、随机试验,比较再程放疗联合贝伐珠单抗与贝伐珠单抗单药治疗复发性胶质母细胞瘤。
- 分层因素包括年龄、切除状态和卡氏功能状态评分(KPS)。
- 纳入标准为复发性胶质母细胞瘤,影像学证据显示肿瘤进展距完成先前放化疗≥6个月。
- 患者按1:1随机分配至再程放疗(35 Gy分10次)联合同步贝伐珠单抗静脉10 mg/kg每2周一次,或贝伐珠单抗单药治疗直至进展。
- 2012年12月至2016年4月共随机分配182例患者,其中170例符合分析。
主要发现
- 中位随访时间(删失患者)为12.8个月。
- 总生存无改善:贝伐珠单抗联合放疗组 vs 贝伐珠单抗单药组的中位生存时间分别为10.1个月 vs 9.7个月,风险比0.98(80%CI 0.79–1.23),P=.46。
- 中位无进展生存:贝伐珠单抗联合放疗组7.1个月 vs 贝伐珠单抗单药组3.8个月,风险比0.73(95%CI 0.53–1.0),P=.05。
- 6个月无进展生存率从贝伐珠单抗单药组的29.1%(95%CI 19.1–39.1)提高至贝伐珠单抗联合放疗组的54.3%(95%CI 43.5–65.1),P=.001。
- 治疗耐受良好:急性3级及以上治疗相关不良事件发生率为5%,无迟发性高级别不良事件。
关键数值与推荐
- 再程放疗剂量为35 Gy分10次,同步贝伐珠单抗静脉10 mg/kg每2周一次。
- 总生存风险比0.98(80%CI 0.79–1.23),P=.46,无显著改善。
- 无进展生存风险比0.73(95%CI 0.53–1.0),P=.05。
- 6个月无进展生存率贝伐珠单抗联合放疗组54.3%(95%CI 43.5–65.1) vs 贝伐珠单抗单药组29.1%(95%CI 19.1–39.1),P=.001。
- 急性3级及以上治疗相关不良事件发生率5%,无迟发性高级别不良事件。
临床怎么用
- 作者认为,再程放疗安全且耐受良好,贝伐珠单抗联合再程放疗在无进展生存方面有临床意义的改善,特别是6个月无进展生存率,但总生存无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS), compared with BEV alone in recurrent glioblastoma (GBM). The primary objective was OS, and secondary objectives included PFS, response rate, and treatment adverse events (AEs) including delayed CNS toxicities. METHODS: NRG Oncology/RTOG1205 is a prospective, phase II, randomized trial of re-RT and BEV versus BEV alone. Stratification factors included age, resection, and Karnofsky performance status (KPS). Patients with recurrent GBM with imaging evidence of tumor progression ≥ 6 months from completion of prior chemo-RT were eligible. Patients were randomly assigned 1:1 to re-RT, 35 Gy in 10 fractions, with concurrent BEV IV 10 mg/kg once in every 2 weeks or BEV alone until progression. RESULTS: From December 2012 to April 2016, 182 patients were randomly assigned, of whom 170 were eligible. Patient characteristics were well balanced between arms. The median follow-up for censored patients was 12.8 months. There was no improvement in OS for BEV + RT, hazard ratio, 0.98; 80% CI, 0.79 to 1.23; P = .46; the median survival time was 10.1 versus 9.7 months for BEV + RT versus BEV alone. The median PFS for BEV + RT was 7.1 versus 3.8 months for BEV, hazard ratio, 0.73; 95% CI, 0.53 to 1.0; P = .05. The 6-month PFS rate improved from 29.1% (95% CI, 19.1 to 39.1) for BEV to 54.3% (95% CI, 43.5 to 65.1) for BEV + RT, P = .001. Treatment was well tolerated. There were a 5% rate of acute grade 3+ treatment-related AEs and no delayed high-grade AEs. Most patients died of recurrent GBM. CONCLUSION: To our knowledge, NRG Oncology/RTOG1205 is the first prospective, randomized multi-institutional study to evaluate the safety and efficacy of re-RT in recurrent GBM using modern RT techniques. Overall, re-RT was shown to be safe and well tolerated. BEV + RT demonstrated a clinically meaningful improvement in PFS, specifically the 6-month PFS rate but no difference in OS.
引用
- Tsien CI, Pugh SL, Dicker AP, et al. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2022. PMID: 36260832. doi:10.1200/JCO.22.00164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。